Trevi Therapeutics Statistics
Total Valuation
TRVI has a market cap or net worth of $311.31 million. The enterprise value is $246.93 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TRVI has 76.87 million shares outstanding. The number of shares has increased by 1.57% in one year.
| Current Share Class | 76.87M |
| Shares Outstanding | 76.87M |
| Shares Change (YoY) | +1.57% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 1.22% |
| Owned by Institutions (%) | 39.03% |
| Float | 47.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.18 |
| P/TBV Ratio | 5.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.38, with a Debt / Equity ratio of 0.02.
| Current Ratio | 7.38 |
| Quick Ratio | 7.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6,887.71 |
Financial Efficiency
Return on equity (ROE) is -59.65% and return on invested capital (ROIC) is -39.89%.
| Return on Equity (ROE) | -59.65% |
| Return on Assets (ROA) | -36.57% |
| Return on Capital (ROIC) | -39.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.77M |
| Employee Count | 25 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -28,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +211.54% in the last 52 weeks. The beta is 0.96, so TRVI's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | +211.54% |
| 50-Day Moving Average | 3.12 |
| 200-Day Moving Average | 2.97 |
| Relative Strength Index (RSI) | 64.87 |
| Average Volume (20 Days) | 4,214,282 |
Short Selling Information
The latest short interest is 1.41 million, so 1.84% of the outstanding shares have been sold short.
| Short Interest | 1.41M |
| Short Previous Month | 1.75M |
| Short % of Shares Out | 1.84% |
| Short % of Float | 2.96% |
| Short Ratio (days to cover) | 2.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.21M |
| Pretax Income | -38.78M |
| Net Income | -44.32M |
| EBITDA | -48.07M |
| EBIT | -48.21M |
| Earnings Per Share (EPS) | -$0.44 |
Full Income StatementBalance Sheet
The company has $65.49 million in cash and $1.11 million in debt, giving a net cash position of $64.38 million or $0.84 per share.
| Cash & Cash Equivalents | 65.49M |
| Total Debt | 1.11M |
| Net Cash | 64.38M |
| Net Cash Per Share | $0.84 |
| Equity (Book Value) | 58.97M |
| Book Value Per Share | 0.78 |
| Working Capital | 58.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$35.07 million and capital expenditures -$50,000, giving a free cash flow of -$35.12 million.
| Operating Cash Flow | -35.07M |
| Capital Expenditures | -50,000 |
| Free Cash Flow | -35.12M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |